Qure confirmed it will submit its BLA in Q3 2026, though there is still a required confirmatory study to conduct.

RLTs were a hot topic at ASCO 2026, but certain limitations must be addressed to facilitate their widespread use in cancer care.

The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.

LG AI Research and D&D Pharmatech have entered into an agreement to collaborate on the development of next-generation oral peptide drugs, the companies announced following a signing ceremony held at ...

Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of TCE multispecific antibodies for GI cancers and other solid ...

Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked TCE therapeutics ...

Zai Lab has received ODD from the EMA for zocilurtatug pelitecan (zoci), its investigational DLL3-targeting ADC for treating pulmonary NECs.

Following the largest dealmaking quarter in six years, PwC analysts have empirically stated that the biopharma ecosystem is “back to full health”. In its midyear outlook report, the firm stated that ...

The Middle East conflict has accentuated long-standing vulnerabilities in the pharma manufacturing supply chain.

Track semiconductor hiring trends by AI jobs, cloud computing, top employers, in-demand skills, and key markets.

Simulations Plus has entered a definitive agreement to be acquired by affiliates of Altaris in an all-cash transaction valued at $375m.

Vedana’s clinical pipeline targets PACAP – an approach that has shown varying levels of success in migraine clinical trials thus far.